Market Signal Briefing

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.

Crypto treasury firms holding Bitcoin, Ethereum, and XRP are recording steep unrealized losses following the latest market downturn. The correction has erased billions from balance sheets of companies that invested heavily in digital assets, exposing the volatility risks of holding crypto as a treasury reserve. Throughout October, market valuations fell sharply, triggering renewed caution among institutional players. 

This shift in sentiment has now spilled over into the broader market, with Bitcoin emerging as the key sentiment driver. As major firms weigh whether to hold or reduce exposure, the Bitcoin price prediction for the coming months hinges on whether bulls can reclaim control or risk deeper declines below the $98,000 mark.

Bitcoin Price Action Suggests Further Weakness Ahead
The current Bitcoin value sits at $101,971, showing continued struggle to hold above key technical thresholds after breaking from its multi-month structure. A clear head-and-shoulders pattern has developed since early October, marking a significant shift in market control. 

The left shoulder formed as prices failed near $110,000, while the head extended toward $114,000 before sellers forced a sharp reversal. By November 4, Bitcoin breached its neckline following a 5% drop, confirming a bearish continuation pattern. 

This technical breakdown signals that downward pressure may persist, especially as buyers fail to defend upper support zones. If the Bitcoin value remains below $103,000, the next likely targets sit near $94,000 and potentially $87,000, two regions that previously acted as major accumulation points. 

However, short-term rebounds near these zones remain possible as bargain buyers step in, attempting to absorb ongoing sell pressure and stabilize the BTC coin price temporarily.

BTC/USD 1-Day (Source: TradingView)
Death Cross Signal Adds Pressure on BTC
The looming death cross on the daily chart continues to strengthen the bearish tone surrounding the Bitcoin price. The 50-day moving average keeps edging lower, closing in on the 200-day line near $110,200 — a formation that often signals deeper corrections ahead. 

Repeated rejections above the 50-day average highlight weakening buying conviction as short rallies face quick sell-offs. 

Meanwhile, macroeconomic stress adds to the pressure. Bitcoin and Ethereum continue to slide as the U.S. government shutdown drags on, shaking investor confidence across both traditional and crypto markets. 

With sentiment deteriorating, the BTC coin price risks another drop toward the $98,000–$94,000 range before any sustainable recovery attempt unfolds. Therefore, traders remain alert as each daily close near these levels grows increasingly critical.

BTC Death Cross Chart (Source: TradingView)
Analyst Warns of Breakdown Toward $98K Before Stability Returns
According to a market analyst, Crypto King, the market’s recent drop toward $100,000 marks the start of a potentially deeper correction phase. The analyst highlights that increasing manipulation by large players and liquidity flushes continue to distort short-term trends. 

He warns that if Bitcoin fails to hold above the $98,000 level, a cascading effect of liquidations could drive the BTC coin price sharply lower, possibly toward mid-$90,000 zones. 

The expert adds that this breakdown reflects exhaustion among retail buyers and fading optimism following the failed push past $110,000. However, the expert remains cautiously optimistic about the BTC’s long-term price forecast, noting that cyclical corrections have historically preceded strong accumulation stages. 

He emphasizes that patience and disciplined buying at deeper supports often set the foundation for recovery once volatility cools. Still, for now, his stance remains bearish, expecting additional weakness before the next sustainable uptrend begins.

BTC/USD Chart (Source: X)
To sum up, Bitcoin stands at a defining moment as technical and sentiment-driven pressures align. The head-and-shoulders breakdown and upcoming death cross strengthen the short-term bearish bias. However, deeper corrections could also create entry points for strategic accumulation, consistent with long-term cycle behavior. For now, the Bitcoin price outlook hinges on whether bulls can defend the $98,000 level or face a sharper slide toward $87,000 before recovery begins.

Crypto treasury firms are under renewed pressure as falling token prices wipe out equity buffers and force more cautious balance-sheet strategies.Bitcoin and altcoin-heavy companies, including Metaplanet, Evernorth, and BitMine, now sit on large unrealized losses amid falling market prices.Analysts say the downturn exposes persistent structural risks, forcing firms to balance long-term conviction with mounting short-term financial strain.Crypto-focused treasury companies are facing renewed strain as the latest market downturn erodes asset values and erases equity cushions that once appeared durable.

In a November 7 post on X, crypto analysis platform CryptoQuant reported that falling token prices have narrowed financial buffers across the sector. That contraction has weakened company valuations, pushing several treasuries to adopt defensive balance-sheet moves in an effort to reassure shareholders.

Sponsored

Bitcoin Treasuries Lean Into Caution as Losses DeepenAccording to the report, Bitcoin-heavy firms are absorbing the sharpest losses. BTC has fallen more than 16% this month and briefly slipped under the $100,000 mark, and that pressure has rippled directly into corporate portfolios.

For context, Strategy, the largest corporate holder of Bitcoin with more than 675,000 BTC, has seen its purchases slow sharply in recent months. The company has shifted from buying thousands of coins to only a few hundred.

Market analysts say the softer buying pace reflects the combined weight of Bitcoin’s slide and Strategy’s weaker equity performance.

As a result, the shift has coincided with a reversal in its MSTR stock price, which has dropped roughly 53% from its all-time high to about $241.93.

MicroStrategy’s MSTR Price Performance. Source: CryptoQuantSponsored

At the same time, Metaplanet, listed on the Tokyo Stock Exchange, finds itself in a similar position.

The company holds 30,823 BTC at an average cost basis of $106,000, leaving it with more than $120 million in unrealized losses at current prices

As a result, its stock has dropped by more than 80% from its peak, compressing market net asset value and prompting a share buyback program designed to restore confidence.

Altcoin Treasuries Absorb Steep MarkdownsAltcoin-focused treasury companies are also feeling the pressure, as the broader market downturn drives steep markdowns across their portfolios.

Sponsored

Their positions have weakened alongside sector-wide declines, adding another layer of strain to an already stressed treasury landscape.

Evernorth, the largest corporate holder of XRP, began accumulating the token in mid-October. However, its 388.7 million XRP tokens are now in an unrealized loss of approximately $79 million.

Evernorth’s Profit and Losses. Source: CryptoQuantOn the other hand, BitMine, the largest Ethereum treasury with more than 3.4 million ETH, is facing even deeper losses.

Sponsored

Ethereum’s recent decline of over 22% in the past month has pushed the company’s unrealized deficit to roughly $2.1 billion.

BitMine’s Ethereum Holdings. Source; CryptoQuantAnalysts say the scale of these drawdowns underscores a recurring structural risk where companies that build positions during periods of strength often experience the fastest erosion of capital when sentiment reverses.

This is in congruence with previous warnings that digital-asset accumulation carries risks that not every firm can absorb.

Considering this, firms now face a sharper test of resilience as they work to maintain long-term conviction in digital assets while absorbing near-term financial pressure. That tension is likely to shape treasury decisions well into next year.

Disclaimer

In adherence to the Trust Project guidelines, BeInCrypto is committed to unbiased, transparent reporting. This news article aims to provide accurate, timely information. However, readers are advised to verify facts independently and consult with a professional before making any decisions based on this content. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

BTC recovered from the sub-$100K drop but what's next?

Bitcoin dropped below $100,000 on a couple of occasions in the past week for the first time since June, which triggered a fresh wave of uncertainty among market observers and participants regarding the bull market’s state.

One of the popular analysts, Ali Martinez, outlined the most crucial support levels if the $100,000 level indeed cracks and BTC decisively enters a five-digit price territory.

Three key Bitcoin $BTC support levels to watch, based on the Pricing Bands:

• $98,340

• $75,475

• $55,980 pic.twitter.com/1tCNyM9J1Z

— Ali (@ali_charts) November 7, 2025

The first one was actually tested during the Tuesday evening crash when BTC dipped below $99,000. So far, it has managed to hold, but if it gives in, then the next ones are situated far below, which would essentially mean the end of the bull market.

However, it’s not all worrying news. Data shared by CW shows that the apparent demand for the asset has returned after a few weeks of obvious absence. The graph below demonstrates that each phase of substantial negative apparent demand has been followed by the complete opposite, which could spell good news for BTC in the short term.

The apparent demand of $BTC has turned positive again.

The market sentiment is changing. Buying demand is increasing again. pic.twitter.com/9tpOUoY0zQ

— CW (@CW8900) November 8, 2025

If bitcoin indeed heads for a more sustained market recovery period, the first major resistance on its way up is at $106,000, followed by $111,600, where more than 140,000 BTC was accumulated. Martinez outlined this level as a “strong resistance barrier” due to this cluster of units purchased at around those levels.

You may also like:

Galaxy Research Slashes Bitcoin (BTC) 2025 Target to $120K Amid Market Turmoil

Bitcoin Dips Below $100K Again as Analyst Waves the White Flag – ‘See You in 4 Years’

Bitcoin Faces Mid-Bull Test with LTHs Cashing Out as STHs Hold the Line

As of press time, BTC remains sideways at around $102,000 after a massive 17.5% decline in the past month. Its market cap sits at $2.030 trillion after it dipped below the crucial $2 trillion level.

Tags:

About the author

Jordan got into crypto in 2016 by trading and investing. He began writing about blockchain technology in 2017 and now serves as CryptoPotato's Assistant Editor-in-Chief. He has managed numerous crypto-related projects and is passionate about all things blockchain.

Key Takeaways
Why is the recent whale transfer fueling renewed optimism for XRP?
Because it signals large-scale accumulation at key support zones, suggesting growing investor confidence.

How are derivatives and on-chain metrics reinforcing XRP’s bullish outlook?
A 247% surge in Funding Rates and stronger network activity reflect revived market momentum.

A massive 42 million Ripple [ XRP], worth approximately $98.6 million, has been transferred from Gemini to an unknown wallet, triggering speculation about large-scale accumulation. 

Historically, such outflows from exchanges suggest that whales are securing assets for long-term holding rather than short-term trading. 

This activity often signals that major investors anticipate a potential rebound following market corrections. 

Moreover, this movement coincides with XRP’s price consolidating near the $2.20–$2.30 support zone, strengthening the idea that institutional players are taking advantage of discounted prices. 

Therefore, this transfer reinforces the growing belief that XRP may be nearing a major turning point.

XRP price tests key support as descending channel narrows
XRP remains locked in a descending channel, moving between $2.20 and $2.65 while showing signs of tightening volatility. 

The repeated defense of the $2.20 support level highlights a significant accumulation area where bullish demand continues to absorb selling pressure. 

At press time, RSI hovered around 42, indicating mild oversold conditions that could support a technical bounce. 

If XRP manages to reclaim the $2.65 resistance, it could trigger a short-term breakout toward $3.12. 

However, if sellers manage to push below the $2.20 threshold, bearish momentum could temporarily strengthen before buyers regain control of the trend.

Source: TradingView

Buyers gain ground as Spot Taker CVD turns bullish
The Spot Taker CVD metric has shifted decisively toward buy-side dominance, suggesting that bullish traders are increasingly active in the market. 

This indicator measures the difference between buying and selling pressure, and its current positive reading highlights growing confidence among spot traders. 

As buyers execute aggressive market purchases, they appear to be front-running potential price reversals near key support zones. 

This rising CVD trend aligns with whale accumulation, showing that both retail and institutional traders are positioning for upside. 

Consequently, the growing buying momentum could limit further downside pressure in the short term.

NVT ratio drop underscores improved network health
At the time of writing, the Network Value to Transaction (NVT) ratio has declined by 30.7% to 75.93, indicating that XRP’s transaction volume is increasing faster than its market capitalization. 

A falling NVT ratio typically signals improved on-chain efficiency, suggesting that the network is processing greater transaction activity relative to its valuation. 

This trend often coincides with undervalued market conditions, hinting at a possible recovery phase. 

Therefore, the decline implies that XRP’s fundamental activity is strengthening even as its price remains subdued. 

If this on-chain improvement continues, it could support renewed investor confidence and drive steady accumulation across the broader market.

Funding Rates surge as long traders regain control
Funding Rates have surged by 247.57%, at press time, highlighting a sharp increase in leveraged long positions on XRP’s perpetual contracts. This spike reflects growing optimism among traders anticipating a short-term rebound. 

When Funding Rates turn highly positive, it typically indicates that more participants are paying premiums to hold long positions, reinforcing bullish bias in the derivatives market. 

However, such aggressive positioning could also heighten liquidation risks if the price fails to sustain momentum. 

Nevertheless, the strong derivatives activity suggests that speculative confidence is returning, creating favorable conditions for a potential breakout above the $2.65 resistance zone.

Ultimately, Whale accumulation, rising buyer dominance, and stronger network activity collectively reinforce a bullish setup for XRP. 

The $2.20 support zone has proven resilient, anchoring renewed confidence across both spot and derivatives markets. 

With buying pressure intensifying and Funding Rates soaring, momentum now favors an upside continuation. 

A decisive push above the $2.65 resistance would establish a clear recovery trend and set the stage for XRP to reclaim higher price ranges in the coming sessions.

Bitwise's spot Dogecoin ETF filing enters automatic approval countdown, potentially launching by November 26 as technical analysis points to $1.20 target if key resistance levels break.

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

The weekend has started with the market bouncing back, according to CoinMarketCap.

Top coins by CoinMarketCapXRP/USDThe rate of XRP has risen by 3.80% over the last day.

Image by TradingViewOn the hourly chart, the price of XRP has made a false breakout of the local support of $2.2745.

You Might Also Like

If the daily bar closes far from that mark, traders may witness local growth to the $2.33 resistance.

Image by TradingViewOn the bigger time frame, the rate of XRP is far from the main levels, which means neither bulls nor bears have accumulated enough energy for a further move. In this case, sideways trading around the current prices is the more likely scenario.

Image by TradingViewFrom the midterm point of view, there are no reversal signals so far. However, if the weekly bar closes far from its low, bulls may seize the initiative, which may lead to a bounce to the $2.50 range.

XRP is trading at $2.2763 at press time.

The XRP market is on edge as it drifts sideways near the $2.30 zone, caught between weak technical momentum and one of the most critical fundamental catalysts of the year — the Franklin Templeton spot XRP ETF decision on November 14. This event, alongside broader macro triggers like the December FOMC meeting, could decide whether XRP breaks free from its multi-month slump or extends its downtrend into winter.

XRP Price Prediction: What the Chart Shows Right NowXRP/USD Daily Chart- TradingViewThe daily chart reflects indecision. XRP trades around $2.29, just above the midline of the Bollinger Bands (20, 2), while the upper band sits near $2.70 and the lower band hovers around $2.19. The candles are compressed, showing reduced volatility and a clear squeeze — a classic setup that precedes a strong directional move.

Volume has thinned, suggesting traders are waiting for confirmation. The Heikin Ashi candles have transitioned from red to mild green in the past few sessions, hinting at early accumulation, though not yet enough to confirm a breakout. If XRP closes decisively above $2.45, the next resistance lies at $2.70, and a rally toward $3.00 becomes possible. On the downside, losing $2.18 could open a slide toward $1.85 and even $1.50 in a risk-off scenario.

How the Franklin Templeton ETF Decision Could Move XRP PriceThis is the near-term catalyst everyone’s watching. If the SEC approves Franklin Templeton’s spot XRP ETF, it would mark the first institutional gateway into XRP exposure after years of regulatory uncertainty. Such approval would legitimize XRP’s post-lawsuit status and could invite new capital from both retail and institutional investors. Historically, ETF approvals have triggered short-term surges of 5–10% followed by sustained uptrends if inflows persist.

A rejection, however, could reinforce the narrative that the SEC remains cautious about XRP’s liquidity and market structure. That might cause a brief selloff toward $2.00 or below, especially if Bitcoin dominance rises at the same time. Expect heightened volatility from November 13–15 as traders price in the decision.

The December 10 FOMC Meeting: Macro Volatility Trigger

The next Federal Open Market Committee (FOMC) meeting is arguably the biggest macro event for all risk assets. If the Fed hints at a rate cut or even a dovish pause, liquidity will flow back into crypto, possibly overriding XRP’s weak technicals. A hawkish tone, on the other hand, could suppress speculative demand across all altcoins.

Crypto’s 0.75 correlation with Nasdaq remains a key metric. A post-FOMC tech rally would likely spill into Bitcoin and large-cap altcoins like XRP, creating short-term upside momentum. Traders should watch the CME FedWatch probabilities — any move above 70% for a 2026 rate cut expectation could turn XRP bullish again.

Bitcoin’s Cycle Peak Model and Ripple Effect on XRP PriceBitcoin’s potential cycle peak around December 22 could mark either the blow-off top or a consolidation phase before another wave higher. If BTC tests $120K–$130K at that time and fails, altcoins might bleed temporarily. Conversely, if institutional inflows push $BTC beyond $130K, XRP could ride the momentum wave, retesting the $3.50 zone by year-end.

Long-Term Perspective: Quantum Computing and Security Fears

While the quantum computing threat projected for 2028 doesn’t directly affect current prices, it shapes long-term investor psychology. Projects like XRP, which rely on ECDSA signatures, may face scrutiny over quantum resistance in coming years. Any proactive move by Ripple Labs to integrate quantum-safe cryptography could serve as a strong narrative catalyst later.

Final XRP Price PredictionThe next 30 days are critical for $XRP. The Bollinger Band squeeze shows pressure building, while upcoming macro and regulatory events could act as release triggers. If the Franklin Templeton ETF gets approved and the FOMC meeting turns dovish, XRP could retest $2.70–$3.00 swiftly. Rejections or hawkish signals, however, might push it down toward $1.85.

Short-term range: $2.18 – $2.70
Bullish breakout target: $3.00 – $3.50
Bearish scenario: $1.85 – $1.50In short, November to mid-December could define XRP’s trajectory for the next year — whether it reclaims its former bullish momentum or remains an underperformer depends entirely on how these catalysts unfold.

📈 Want to Trade XRP?Start now on Bitget: Sign Up Here
Check Live XRP Chart: XRP/USDT on Bitget

or You an check the Crypto Exchange Comparison.

Key takeaways:

Older Bitcoin whales are selling heavily, spending over 1,000 BTC/hour in 2025.

Bitcoin’s bear pennant pattern projects a potential drop to $89,600. 

Bitcoin (BTC) was at risk of further losses as the oldest whales continued to spend their BTC stash. 

Capriole Investments co-founder Charles Edwards said that “super whales are cashing out of Bitcoin,” in a post on X, raising concerns about the potential impact on BTC’s price.

Bitcoin OG whales keep dumpingWhile some view this as a normal dip for bull cycles, others argue that the correction has been fueled by selling from long-term holders. 

Edwards shared a chart illustrating the extent of onchain spending from “OG” Bitcoin holders—those who have held their assets for seven years or more.

The chart features two color-coded categories: orange for $100 million dumps and red for $500 million dumps, clearly demonstrating the scale of selling by these long-term investors. This selling began in November 2024 and intensified in 2025.

“The chart is VERY colorful in 2025,” Edwards said, adding:

“OGs are cashing out.”Bitcoin OG whale dumping. Source: GlassnodeAdditional data from Glassnode shows that events where these whales have been spending more than 1,000 BTC per hour have been persistent since January.

“The key distinction in this cycle is that these OG whale high-spending events occurred more frequently throughout, signalling persistent distribution.“Bitcoin OG whale spending events. Source: GlassnodeOne such example is “Bitcoin OG Owen Gunden,” highlighted by onchain analytics platform Lookonchain. This whale has moved 3,600 BTC, worth about $372 million, on Saturday, with “500 $BTC($51.68) already deposited to Kraken.”

— Lookonchain (@lookonchain) November 8, 2025
Despite this selling pressure, the market has exhibited unusual resilience, according to Willy Woo, who argues that “what constitutes an ‘OG dump’ is simply BTC moving out of an address that has been untouched for 7 years.”

Willy Woo suggested that BTC transfers by long-term holders may be intended for moving to taproot addresses for quantum-safe transactions. He notes that these could also involve custody rotations or seeding BTC treasury companies, rather than actual sales.

Bitcoin “bear pennant” targets $90,000Data from Cointelegraph Markets Pro and TradingView shows BTC trading inside a bear pennant, suggesting that a significant downward move may be next.

A bear pennant is a downward continuation pattern that occurs after a significant drop, followed by a consolidation period at the lower end of the price range.

A break below the pennant’s support line at $100,650 could potentially lead to the next leg down for Bitcoin, measured at $89,600 or a 12% decline from its current price level.

BTC/USD six-hour chart. Source: Cointelegraph/TradingViewAs Cointelegraph reported, Bitcoin must close the week above the 50-week EMA, currently at $100,900, to avoid a deeper correction toward $92,000 or lower.

This article does not contain investment advice or recommendations. Every investment and trading move involves risk, and readers should conduct their own research when making a decision.

Bitcoin News: Whales Accumulate at $100K$Bitcoin continues to show resilience around the $100,000 mark, with large holders — wallets holding between 1,000 and 10,000 BTC — significantly increasing their accumulation. On-chain data from CryptoQuant shows that whale balances are rising again, with the 7-day balance change turning sharply positive, signaling that major investors are buying the dip.

This renewed accumulation phase follows weeks of correction, suggesting that large holders view the current range as a strategic accumulation zone before the next leg up. Historically, similar balance surges have preceded strong bullish moves in Bitcoin’s price.

On-Chain Analysis: Whale Confidence ReturnsThe total balance of whale wallets now sits around 3.5 million $BTC. The purple indicator highlights a noticeable uptick — a clear sign of returning confidence among institutional players and long-term holders.

As accumulation strengthens, the selling pressure from short-term traders appears to weaken. This behavioral shift often occurs before key breakouts, aligning with previous mid-cycle consolidations. The takeaway: whales are betting on a rebound.

Liquidation Map: $9.6 Billion in Shorts at RiskAnother chart reveals a massive liquidation cluster forming near $115,000, where over $9.6 billion worth of short positions could be wiped out if Bitcoin rallies past this level.

Currently trading around $103,500, Bitcoin sits just below a critical threshold that could trigger a cascade of short liquidations — particularly across Binance and OKX. This liquidity wall could amplify upward momentum if the price begins to move higher.

Such liquidation-driven short squeezes have historically accelerated Bitcoin’s price movements, turning minor rallies into explosive breakouts.

Bitcoin Price Prediction: $115K Is the Line to WatchIf Bitcoin continues to hold above $100K while whales keep accumulating, a breakout above $110K–$115K could ignite a liquidation rally toward $125K or higher. Conversely, failure to defend the $100K level could reopen the path to $97K–$95K, where strong support lies.

BTC/USD 1-day chart - TradingView

The data suggests that the market’s next major move will depend on whether bulls can force shorts to capitulate. For now, smart money seems to be preparing for that very scenario.

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Bitcoin’s mining industry is feeling growing strain as the key profitability gauge, hash price, slides toward levels that could push smaller operators offline and put pressure on mining equipment providers and service partners.

Hash Price Nears Danger Level
According to industry reports, hash price — the expected daily revenue per unit of computing power — is about $42 per PH/s today, down from above $62 per PH/s in July.

That dip toward the $40 mark is forcing some smaller and less efficient miners to weigh powering down their rigs. Reports have disclosed that when revenue falls this far, operators with thin margins can no longer cover power and maintenance bills.

Hardware makers and hosting firms are being affected. Orders for machines have slowed, and any income tied to Bitcoin has lost value after the market slide in October.

Some manufacturers have started mining with their own machines to offset weaker customer demand. Bitdeer and similar firms have been reported to expand self-mining operations to fill gaps in sales.

Hash price drops and approaches a critical level. Source: TheMinerMag
Miners Move Into AI Compute
High capital costs and steady increases in hashrate make running ASIC farms tougher, especially after the April 2024 halving cut the block reward to 3.125 BTC.

Back in 2009, the block reward was 50 BTC and people could mine with CPUs. Today, only specialized hardware makes mining viable for most operators. That shift has pushed some companies to convert capacity into general compute for AI workloads.

Based on reports, big deals show the trend is real. Cipher Mining signed a $5.5 billion, 15-year deal to supply compute power to Amazon Web Services in October.

IREN later agreed to provide GPU services to Microsoft in a contract valued at $9.7 billion. These moves are meant to bring steady revenue when Bitcoin mining profits shrink.

BTCUSD now trading at $102,248. Chart: TradingView
Market Slump Adds To Miner Stress
Bitcoin’s price weakness has compounded the problem. The token briefly fell below $100,000, trading as much as 20% below the October 6 high of above $126,000.

Analysts point to heavy selling by long-term holders: since late June, net sales from that group have topped 1 million bitcoin, according to Compass Point analyst Ed Engel.

A large liquidation of leveraged positions on Oct. 10 also shook the market and knocked out support levels near $117,000 and $112,000.

Image: Dragos Condrea / Getty Images
Markus Thielen, founder and CEO of 10X Research, said the market’s failure to reclaim key levels suggests bearish conditions, and his firm maintains that bitcoin could still fall further before a bottom appears.

His team had earlier forecast a drop to $100,000 and now says a buyable bottom may be “a few weeks away.”

Featured image from Pexels, chart from TradingView

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Pi Network price remains in a tight range as the recent rally faded. Still, the token could be on the verge of a rebound after forming a bullish pattern, and as a top whale restarts purchases.

Summary

Pi Network price has wavered in the past few weeks.
A Pi whale has bought over 5.3 million tokens in the last 9 days. 
This accumulation could be a sign of an eventual rebound.

Pi Coin (PI) token was trading at $0.2240, a range it has remained at in the past few days. It has plunged by over 90% from its highest point this year. 

One potential catalyst is that an anonymous whale who was accumulating it a few months ago has resumed buying. Data compiled by PiScan shows that the biggest Pi whale has bought over 5.3 million tokens in the last 9 days after a two-month hiatus.

The whale now holds over 371 million tokens worth over $82 million. He has made over $40 million in losses as the coin plunged to a record low in October. 

These purchases are signs that he expects the token to rebound in the coming weeks or months. One potential catalyst for the recovery is that the team has made some notable progress recently.

They have deployed some of the $100 million ecosystem fund launched in May. They invested in OpenMind, a company in the AI and robotics industries. As part of the investment, the two sides conducted a trial that allows pioneers to support the training of its AI models. 

Pi Network and OpenMind’s proof-of-concept project, where OpenMind’s AI models can run on Pi Node infrastructure, explores the capability of Pi’s global network of nodes to support decentralized AI training and computing tasks.

By transforming unused computing power into… pic.twitter.com/8GN9UDNy8J

— Pi Network (@PiCoreTeam) November 3, 2025

Pi Network also launched a testnet for decentralized exchanges, liquidity providers, and automated market makers. The mainnet will enable the launch of these exchanges on its blockchain. 

Additionally, they have launched an AI model to fast-track the verification of pioneers. This model has conducted a KYC process on millions of users in the past few months.

Pi Network price technical analysis 
Pi Coin price chart ~ Source: crypto.news
The daily timeframe chart shows that the value of Pi has remained under pressure in the past few months. Most recently, however, it has formed a falling wedge pattern, a popular bullish reversal sign. 

It has already moved above the upper side of this wedge, confirming a break-and-retest pattern. Also, the token has formed a bullish divergence as the Relative Strength Index and the Percentage Price Oscillator have moved upwards.

Therefore, the token will likely rebound and hit the resistance at $0.50, which is about 127% above the current level. A drop below the all-time low of $0.1493 will invalidate the bullish outlook.

Disclosure: This article does not represent investment advice. The content and materials featured on this page are for educational purposes only.

Ocean Power Technologies Inc (NYSE-A:OPTT) earlier this week highlighted that it had received certification from the Association for Uncrewed Vehicle Systems International (AUVSI) to provide training for operators of uncrewed surface vehicles (USVs).

The company said the accreditation recognises its ability to deliver ethical, safe, and efficient training. It noted that operators who complete the course can demonstrate certified proficiency in using USVs, supporting broader deployment of autonomous maritime systems.

CEO Philipp Stratmann told Proactive that while many in the industry discuss autonomy, actual operations still depend on skilled human oversight. “They all have to be operated,” he said, underlining the practical need for certified training.

The company explained that its training curriculum is based on operational knowledge gained from deployments in a range of environments, including hot-weather operations in the UAE and cold-weather scenarios in the Baltic. These experiences are fed into Ocean Power Technologies’ processes and used to continually refine its offerings.

Stratmann noted that the company’s ISO 9001 certification supports this iterative improvement. He added that all feedback from field teams and technical staff is used to enhance the quality of future deployments.

Ocean Power Technologies stated that this milestone adds formal rigour to its training and creates a new commercial opportunity. The training programmes are expected to generate revenue for the company, in addition to supporting the transition from demonstration activities to full operational deployment of autonomous systems.

“This is going to be one of those cornerstones that enables the true operationalising of USVs and autonomous operations on the ocean,” Stratmann said. He also mentioned the potential to include other technologies such as buoys in these integrated solutions.

The company believes this step strengthens its position in supporting large-scale adoption of ocean autonomy technologies. Stratmann said it reflects Ocean Power Technologies’ broader objective of enabling customers to fully benefit from autonomy and self-reliance at sea.

With stocks wobbling in the past week over potential AI valuation worries, investors might have noticed that much of the Magnificent Seven has been increasingly choppy while Apple (NASDAQ:AAPL) has acted like a steady rock, holding its ground at around $270 per share.

There's no need to break the bank to get your hands on excellent dividend payers.

The stock market caters to investors with almost any budget, especially with online brokers offering commission-free trading and fractional shares. Even with a modest sum, you can find quality stocks across many investing styles: growth, value, buy-and-hold, and, of course, dividend-oriented.

While many of the top income stocks on the market are expensive, some can be had for well under $100 per share. Here are two examples: Coca-Cola (KO +2.16%) and Pfizer (PFE +0.10%).

Image source: Getty Images.

1. Coca-Cola
Any company capable of increasing its dividend for 63 consecutive years, as Coca-Cola has done, is worth serious consideration for income investors. The company has achieved this rare streak thanks to several factors, including a genius marketing ability that made it one of the most recognizable brands in the world.

Coca-Cola now doesn't need to work quite as hard to attract willing buyers. And its products remain in relatively high demand regardless of economic conditions, allowing it to continue increasing its dividend even when the economy isn't doing well or during bear markets. That's precisely what dividend seekers want.

But there's more. Coca-Cola has many tools in its arsenal that allow it to continue growing revenue and earnings at a decent clip while maintaining strong margins. One of them is to launch new products or brands as consumers grow tired of older ones. This helps inject some excitement into an otherwise "boring" business. New products it has launched over the past two years under well-known brands include Coca-Cola Spiced and Simply Pop, a line of prebiotic sodas.

Today's Change

(

2.16

%) $

1.49

Current Price

$

70.55

It's hard for newcomers to steal significant market share from Coca-Cola. Whatever innovation they come up with, the beverage giant can launch its own version that's almost guaranteed to be more successful, given its brand name. That's how it has built an extensive portfolio of products across almost every beverage category in existence.

Something else Coca-Cola routinely does is raise prices on various items, which can help it fend off threats like tariff impacts. And once again, it can do so without losing significant sales, which provides more evidence of its incredibly strong business.

These (and other) factors explain Coca-Cola's long and storied track record, and the company still has many years of dividend increases ahead. Meanwhile, shares are trading at just under $69 apiece. At that price, there aren't many better dividend stocks to buy and hold for a long time.

2. Pfizer
Pfizer's financial results have been pretty bad in recent years, and that continues to be the case. Revenue in the third quarter declined 6% year over year to $16.7 billion, while adjusted earnings per share fell 18% to $0.87. Yet the pharmaceutical giant reaffirmed its revenue guidance and raised its earnings guidance for the full year 2025.

One reason Pfizer's bottom line could come in ahead of its own expectations is that cost-cutting initiatives are going even better than expected. The company projects that it will achieve net cost savings of $7.2 billion by the end of 2027. Meanwhile, a recent deal it made with the U.S. government will allow it to avoid tariffs for three years. So, the drugmaker is making moves that will help boost operating margins and the bottom line.

Today's Change

(

0.10

%) $

0.03

Current Price

$

24.45

But can it boost revenue growth? Pfizer has earned approval for newer products in recent years while significantly expanding its pipeline through acquisitions. We have yet to see the results of those efforts on the company's financial results. In fairness, that won't happen immediately, especially as it will face a patent cliff for Eliquis, an anticoagulant that's one of its best-selling medicines, within the next few years.

Even so, at a price of about $25 per share and a recent forward price-to-earnings (P/E) ratio of 8.7 -- the average for the healthcare industry is 17.1 -- the stock looks cheap right now, at least for investors willing to stick with the company through the next five years and beyond as it replenishes its lineup of medicines.

Pfizer also currently offers a juicy forward yield of around 7%, well above the S&P 500's average of 1.2%. The stock may be down right now, but patient investors should be rewarded.

November 08, 2025 9:27 AM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 8, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting from allegations that Telix may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Telix securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=43778 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On July 22, 2025, Telix disclosed receipt of a subpoena from the U.S. Securities and Exchange Commission, which was "seeking various documents and information primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutic candidates."

On this news, Telix's American Depositary Share ("ADS") price fell 10.44% on July 23, 2025.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273629

HomeIndustriesAutomobilesThere are two ‘limiting factors’ on Tesla’s future, the CEO said, that could keep him from reaching the objectives that would get him paidPublished: Nov. 8, 2025 at 9:30 a.m. ET

Tesla CEO Elon Musk has made artificial intelligence and robotics a key part of the company’s future. Photo: Getty ImagesTesla Inc. investors have given Chief Executive Elon Musk a path to earn some $1 trillion worth of company shares.

But getting there won’t be easy, especially if Tesla can’t overcome two major issues.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of T either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company’s strong presence at BIO-Europe 2025 and the growing momentum behind its late-stage clinical programs.

Vitt discussed the progress of Immunic’s lead asset vidofludimus calcium, particularly its ongoing ENSURE Phase 3 trials for multiple sclerosis, which are fully enrolled and expected to report data at the end of 2026.

In addition, Dr Vitt pointed to continued progress in Immunic’s gastrointestinal program, IMU-856, which has shown promising data in celiac disease and GLP-1 upregulation. The company is exploring further development and potential partnerships for this asset.

Proactive: Hello you're watching Proactive, I'm joined by Dr Daniel Vitt, the CEO of Immunic. Daniel, very good to speak with you. You've just attended BIO-Europe 2025, which brought together industry leaders from across the world in Vienna. How would you describe the atmosphere at this year’s conference?

Dr Daniel Vitt: It's a very exciting, active, energetic meeting — a lot of areas covered. I think it’s maybe in Europe one of the most important conferences, which brings together investors, business development people, and science. So I think it’s really a broad coverage. I also see a lot of international attendance from the US and also from Asia. So it's an important meeting.

At the conference, the international biotech community was brought together in a German-speaking setting. So a natural fit for Immunic with its German roots. How did this year's location and audience support your goals?

Well, it was in a German-speaking country, but it was a very international meeting. It's English-speaking at the end. For us, it’s good to be present there because we do a lot in the US on networking, being in New York. I think it’s clearly US-focused, and it’s good to also have direct access to companies and investors in Europe. So, yeah, it was good to be there.

And what kind of feedback did you receive on Immunic’s clinical programs and scientific direction, and are there any insights that particularly stood out?

It’s all about multiple sclerosis right now. We have two things we speak about and where we got all the interest from external partners. It's really about our Phase 3 ENSURE studies. As you remember, these studies are fully enrolled, and we expect them to read out at the end of next year. So we’re now running into the year of Phase 3 readouts for the company. This is an important step not only in the context of business development but also for investors. I think it's a unique growth story and has the ability to address a multi-billion market opportunity. Vidofludimus calcium is positioned very nicely as a dual acting molecule, being a first-in-class Nurr-1 activator. It really makes it exciting for a lot of people.

But we also see interest in our GI program, IMU-856, where we have reported very nice proof-of-concept data from celiac disease. And going forward, in the context of a recent report, additional data showed that the drug in celiac disease patients has shown upregulation of GLP-1. That makes it quite an interesting opportunity as well. So all in all, it was a diverse discussion with investors and potential partners for both programs — a good experience.

Daniel, as you return from Vienna, how did the insights and connections from BIO-Europe shape Immunic’s outlook and priorities moving forward?

Well, it’s all in the context of our strategy. On the one hand, bringing vidofludimus calcium to the market, and as a next step, to read out the Phase 3 data next year. And of course, also to progress or find good ways to progress IMU-856 in clinical trials and develop it further. A partnership could be a good path here. It fits nicely into the global context of the work we’re doing and the discussions and meetings we are having in the United States, and also in upcoming conferences like the Jefferies Healthcare Week in two weeks.

Quotes have been lightly edited for clarity and style

Pfizer acquires Metsera for $10 billion, cementing their new obesity treatment strategy. The purchase concludes a weeklong bidding frenzy between the New York-based pharmaceutical company and Danish heavyweight Novo Nordisk, whose last-minute counterbid was finally rejected by US antitrust regulators.

-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025-

-Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in circulating ANGPTL3 with a mean reduction from baseline of -73% (maximum -89%), a mean reduction in triglycerides (TG) of -55% (maximum -84%), and a mean reduction of low-density lipoprotein (LDL) of -49% (maximum -87%) at the highest dose-

-Among participants with elevated baseline TG (>150 mg/dL), a mean reduction of 60% in TG were observed at therapeutic doses-

-CTX310 was well tolerated with no treatment-related serious adverse events and no ≥Grade 3 changes in liver transaminases-

-Findings simultaneously published in The New England Journal of Medicine entitled “First-in-Human Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3”-

ZUG, Switzerland and BOSTON, Nov. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced positive Phase 1 data from its ongoing clinical trial evaluating CTX310®, an investigational, in vivo CRISPR/Cas9 gene-editing therapy targeting ANGPTL3. A single-course treatment with CTX310 produced dose-dependent, durable reductions in circulating ANGPTL3 with a mean reduction from baseline of -73% (maximum -89%), a mean reduction in triglycerides (TG) of -55% (maximum -84%) and a mean reduction of low-density lipoprotein (LDL) of -49% (maximum -87%) at the highest dose. These data demonstrate the potential of CTX310 to deliver meaningful and sustained lipid lowering following a single-course intravenous (IV) infusion.

These data were presented today during a late-breaking session at the American Heart Association (AHA) Scientific Sessions and published simultaneously in The New England Journal of Medicine (NEJM) in a peer-reviewed article entitled “Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3.”

"The publication and presentation of these Phase 1 results mark an important milestone for CRISPR Therapeutics and for the field of in vivo gene editing,” said Naimish Patel, M.D., Chief Medical Officer of CRISPR Therapeutics. “For the first time, we’ve shown that a single-course in vivo CRISPR treatment can safely and durably lower ANGPTL3, leading to clinically meaningful reductions in triglycerides and LDL. These data provide strong support for continued advancement of CTX310 and our broader cardiovascular gene-editing portfolio.”

“Seeing a single-course treatment safely lower both LDL cholesterol and triglycerides is truly unprecedented,” said Stephen J. Nicholls, lead study investigator and director of the Victorian Heart Institute at Monash University. “If these findings are confirmed in larger studies, a one-time therapy could redefine how we manage lifelong lipid disorders and help prevent cardiovascular disease.”

“Adherence to cholesterol-lowering therapy remains a major challenge in treating patients with heart disease,” said Steven E. Nissen, M.D., senior author of the study and Chief Academic Officer at the Cleveland Clinic Heart, Vascular and Thoracic Institute. “Many patients discontinue therapy within the first year. The prospect of a one-time treatment with durable effects would be a major advance in cardiovascular prevention.”

CTX310

CTX310 is an investigational, lipid nanoparticle (LNP) delivered CRISPR/Cas9 therapy designed to precisely edit the ANGPTL3 gene in hepatocytes following a single-course IV administration. ANGPTL3 encodes a key protein that regulates TG and LDL levels, both well-established risk factors for atherosclerotic cardiovascular disease (ASCVD). Individuals with naturally occurring loss-of-function mutations in ANGPLT3 have lower TG, lower LDL and a reduced lifetime risk of cardiovascular disease compared to those without such mutations. By reducing ANGPTL3 expression, CTX310 has the potential to durably lower TG and LDL cholesterol in patients with severe or refractory dyslipidemia. More than 40 million people in the United States have elevated TG, elevated LDL, or both, underscoring the significant unmet medical need. CTX310 is initially being developed for patients at highest cardiovascular risk who have limited effective treatment options despite current lipid-lowering therapies.

Phase 1 Clinical Trial Design

The Phase 1, open label, dose-escalation trial evaluated single-course IV doses of CTX310 ranging from 0.1 to 0.8 mg/kg (lean body weight) targeting ANGPTL3 in four patient groups: homozygous familial hypercholesterolemia (HoFH), severe hypertriglyceridemia (sHTG), heterozygous familial hypercholesterolemia (HeFH), or mixed dyslipidemias (elevated TG and LDL). Eligible participants had uncontrolled TG levels >150 mg/dL and/or LDL cholesterol >100 mg/dL (or >70 mg/dL for those with established ASCVD) despite background standard of care per local guidelines.

The majority of participants were receiving statins and/or ezetimibe, while 40% were taking PCSK9 inhibitors. The trial was designed to evaluate safety and tolerability as primary endpoints, with changes in circulating ANGPTL3 protein, TG, and LDL as secondary endpoints.

Safety and Tolerability

Single-course ascending doses of CTX310 were administered to 15 participants across sequential cohorts, and all participants completed at least 28 days of follow-up as of the data cutoff. CTX310 was generally well tolerated, and no dose-limiting toxicities or serious adverse events related to treatment.

Adverse events were generally mild to moderate. One participant experienced an allergic reaction that resolved the following day with supportive care. Infusion-related reactions occurred in three participants (two at 0.6 mg/kg and one at 0.8 mg/kg dose), all Grade 2. All events resolved, and all participants completed their infusions. One participant with elevated transaminases level at baseline had a Grade 2 elevation of transaminases that peaked by Day 4 and resolved completely by Day 14 without any rise in bilirubin.

Overall, CTX310 demonstrated a well-tolerated safety and tolerability profile that supports continued advancement of the program.

Efficacy Highlights

These new results build upon previously disclosed top-line data from 12 participants across the first four sequential cohorts, corresponding to lean body weight-based doses of DL1 [0.1 mg/kg], DL2 [0.3 mg/kg], DL3 [0.6 mg/kg] and DL4 [0.8 mg/kg]. All participants had at least 30 days of follow-up.

Dose-dependent reductions in circulating ANGPTL3 protein: Mean (range) among participants treated with 0.1, 0.3, 0.6, 0.7, and 0.8 mg/kg doses were 10% (-22 to 71), 9% (-25 to 64), -33% (-51 to -19), -80% (-87 to -73), and -73% (-89 to -67), respectively, at Day 30 following CTX310 infusion.Among participants treated at 0.8 mg/kg, TG reductions of up to 84% were observed, with a mean reduction of 55% at Day 60 following CTX310 infusion. In participants with elevated TG (>150 mg/dL) at baseline, mean reductions of 60% were observed at the therapeutic dose levels at Day 60 following CTX310 infusion.   Among participants treated at 0.8 mg/kg, LDL reductions of up to 87% were observed, with a mean reduction of 49% at Day 60 following CTX310 infusion.Two participants on background PCSK9 inhibitors achieved >80% reduction in LDL from baseline. Next Steps

Results from the Phase 1 clinical trial highlight the potential of CTX310 to safely and durably lower both TG and LDL following a single-course IV administration. These findings underscore its promise as a potentially transformative treatment approach for patients with severe or refractory dyslipidemia. CRISPR Therapeutics is advancing CTX310 into Phase 1b clinical trials, prioritizing development in sHTG and mixed dyslipidemia.

About In Vivo Programs 
CRISPR Therapeutics has established a proprietary lipid nanoparticle (LNP) delivery platform to enable gene editing in the liver using both CRISPR/Cas9 and its novel, proprietary SyNTase™ editing technologies. The Company’s in vivo portfolio includes its lead investigational programs, CTX310 (directed towards angiopoietin-related protein 3 (ANGPTL3)) and CTX320™ (directed towards LPA, the gene encoding apolipoprotein(a) (apo(a)), a major component of lipoprotein(a) [Lp(a)]). Both are validated therapeutic targets for cardiovascular disease. CTX310 and CTX320 are in ongoing clinical trials in patients with heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, mixed dyslipidemias, or severe hypertriglyceridemia, and in patients with elevated lipoprotein(a), respectively. In addition, the Company’s research and preclinical development candidates include: CTX460™, targeting SERPINA1 for the treatment of alpha-1 antitrypsin deficiency (AATD); CTX340™, targeting AGT for the treatment of refractory hypertension; and CTX450™, targeting ALAS1 for the treatment of acute hepatic porphyria (AHP). 

About CRISPR Therapeutics
Founded over a decade ago, CRISPR Therapeutics is a leading gene editing company focused on developing transformative medicines for serious diseases. The Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, approved for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. CRISPR Therapeutics is advancing a broad and diversified pipeline across hemoglobinopathies, oncology, regenerative medicine, cardiovascular and autoimmune, and rare diseases. The Company continues to expand its leadership in gene editing through the development of SyNTase™ editing, a novel and proprietary gene-editing platform designed to enable precise, efficient, and scalable gene correction. To accelerate and expand its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com. 

CRISPR THERAPEUTICS® standard character mark and design logo, SyNTase™, CTX310®, CTX320™, CTX340™, CTX450™ and CTX460™ are trademarks and registered trademarks of CRISPR Therapeutics AG. CASGEVY® and the CASGEVY logo are registered trademarks of Vertex Pharmaceuticals Incorporated. All other trademarks and registered trademarks are the property of their respective owners.  

CRISPR Therapeutics Forward-Looking Statement
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements made by Drs. Nicholls, Nissen and Patel in this press release as well as statements regarding any or all of the following: (i) CRISPR Therapeutics preclinical studies, clinical trials and pipeline products and programs, including, without limitation, manufacturing capabilities, status of such studies and trials, potential expansion into new indications and expectations regarding data, safety and efficacy generally; (ii) data included in the above-described oral presentation and any associated abstracts or posters, data included in the above-described article in The New England Journal of Medicine as well as the ability to use data from ongoing and planned clinical trials for the design and initiation of further clinical trials; and (iii) the therapeutic value, development, and commercial potential of gene editing technologies and therapies, including CRISPR/Cas9 and SyNTase, as well as other technologies. Risks that contribute to the uncertain nature of the forward-looking statements include, without limitation, the risks and uncertainties discussed under the heading “Risk Factors” in CRISPR Therapeutics most recent annual report on Form 10-K and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. We disclaim any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

Investor Contact: 
+1-617-307-7503 
[email protected]

Media Contact: 
+1-617-315-4493 
[email protected]

Investing in companies powering the global AI infrastructure buildout can be a smart long-term strategy.

The U.S. equity market has been volatile in 2025, demonstrating sharp swings and record-breaking highs. However, investors seem to remain optimistic, considering that the AAII Sentiment Survey registered at 44.03% bullish at the end of October, higher than its long-term average of 37.6%. 

The technology-heavy Nasdaq Composite index is currently up by 23.4% so far in 2025. Despite concerns about rising inflation and interest rate cuts, corporate earnings are growing at an exceptional pace.

Against this backdrop, it makes sense to pick stakes in companies with sustainable growth drivers, large addressable markets, and clear competitive advantages. Here's why I think these three exceptional stocks are strong buys now.

Image source: Getty Images.

Alphabet
Alphabet (GOOG 1.94%) (GOOGL 2.00%) has surpassed the $100 billion quarterly revenue milestone for the first time in its history, in the third quarter of its fiscal 2025. The company's net income also soared 33% year over year to roughly $35 billion. This demonstrates that while artificial intelligence (AI) was previously perceived as a threat, the company has successfully leveraged it into a high-margin opportunity.

The company's AI Overviews and AI Mode features are already driving higher volumes of total queries and commercial queries for the Search business. The monetization of advertisements below and within the response in AI Overviews (which is at baseline) is at the same rate as in traditional search.

Google Cloud is also benefiting from the explosive demand for AI infrastructure services, with revenue soaring 34% year over year to $15.2 billion and an operating margin of 23.7% in the third quarter. The cloud business's contracted backlog also grew 82% year over year to $155 billion at the end of the third quarter, suggesting strong multi-year revenue visibility.

Today's Change

(

-1.94

%) $

-5.53

Current Price

$

279.81

Some investors may be concerned about Alphabet's heavy projected capital investment of nearly $91 billion to $93 billion in AI initiatives and the subsequent jump in depreciation expenses in 2025. However, while the company's strategy of investing in data center capacity may prove painful in the short run, it can translate into impressive share price gains for Alphabet in the next few years.

Broadcom
Broadcom's (AVGO 1.84%) custom AI chips and networking solutions have become mission-critical in the global AI infrastructure buildout. Besides its three major hyperscaler clients, the company has secured orders worth over $10 billion for racks of AI accelerators from a fourth prominent hyperscaler customer.

Additionally, the company has also partnered with OpenAI to develop and deploy the latter's 10-gigawatt worth of custom chips starting in the second half of 2026. Anthropic has expanded its partnership to utilize Alphabet's nearly one million tensor processing units (TPUs), which will increase its compute capacity by over 1 gigawatt by 2026. Broadcom is expected to benefit, as it has been the primary co-designer for these TPUs.

Today's Change

(

-1.84

%) $

-6.54

Current Price

$

349.05

Broadcom's networking chips, such as the Tomahawk 6 switch and Jericho fabric routers, are being used widely to enable low-latency and high-bandwidth networking in large AI clusters, within data centers, as well as between data centers located at different sites. Infrastructure software has also become a key growth engine, with revenue increasing 17% year over year to $6.8 billion and accounting for 43% of the company's total revenue.

The company's revenue was up 22% year over year to $16 billion, while adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) margin was 67% in the third quarter. With a contracted backlog of $110 billion, Broadcom is well-positioned to continue posting impressive results in the coming quarters.

Amazon
Amazon (AMZN +0.64%) has stepped back into the spotlight, driven by reacceleration in growth at its cloud computing business, AWS. In the third quarter, AWS revenue increased 20.2% year over year to $33 billion, putting the business on an annualized run rate of $132 billion.

Amazon's broad infrastructure and complete control of the technology stack enabled it to attract several prominent customers. Anthropic is currently using Amazon's project Rainier, involving multiple U.S. data centers with nearly 500,000 Trainium2 chips, to train the next version of the Claude AI model. The company expects Anthropic to use more than one million Trainium 2 chips by the end of 2025.

Amazon has also entered into a $38 billion deal with OpenAI, allowing the latter to run its core AI workloads on AWS for the next seven years. These deals highlight AWS' execution capabilities at massive scale, especially for complex AI workloads. AWS also has exceptional multi-year revenue visibility.

Today's Change

(

0.64

%) $

1.56

Current Price

$

244.60

Besides AWS, advertising is also a significant high-margin growth engine, with revenue growing 22% year over year to $17.7 billion in the third quarter. The e-commerce business is also becoming strong, as the company focuses on same-day delivery and expansion in rural areas.

Amazon's revenue increased 13.4% year over year to $180.2 billion, and operating income was $17.4 billion in the third quarter. The company has added 3.8 gigawatts of data center capacity over the last 12 months and expects to double capacity by 2027. Amazon has also guided for capital expenditures to be around $125 billion in 2025 and even higher in 2026. Not surprisingly, rising depreciation expenses can put pressure on margins over the next couple of years.

Despite this, Amazon is riding several robust AI-powered tailwinds and is balancing growth and profitability. Hence, the payoff for investing in this stock seems attractive for a long-term investor.

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of RCI Hospitality Holdings, Inc. (NASDAQ: RICK) between December 15, 2021 and September 16, 2025, both dates inclusive (the "Class Period"), of the important November 20, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.

So what: If you purchased RCI Hospitality securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the RCI Hospitality Holdings class action, go to https://rosenlegal.com/submit-form/?case_id=44953 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 20, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Defendants engaged in tax fraud; (2) Defendants committed bribery to cover up the fact that they committed tax fraud; (3) as a result, defendants understated the legal risk facing the company; and (4) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. 

To join the RCI Hospitality Holdings class action, go to https://rosenlegal.com/submit-form/?case_id=44953 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY  10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Study Also Shows 36% Reduction in Risk of Heart Attack 

Repatha is the First and Only PCSK9 Inhibitor to Significantly Reduce the Risk of First Heart Attack and Stroke

, /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (evolocumab) achieved statistically significant and clinically meaningful reductions in major adverse cardiovascular events (MACE) in high-risk adults without a prior heart attack or stroke, when added to statins or other low-density lipoprotein cholesterol (LDL-C)–lowering treatments. Repatha is the first and only PCSK9 inhibitor to demonstrate a significant reduction of cardiovascular events as both high-risk primary and secondary prevention. The results were presented in a late-breaking session at the 2025 American Heart Association Scientific Sessions and simultaneously published in the New England Journal of Medicine. 

In this landmark study of more than 12,000 patients with atherosclerosis or diabetes who had no prior heart attack or stroke, Repatha demonstrated a 25% relative reduction in the risk of a composite of coronary heart disease (CHD) death, heart attack or ischemic stroke (3-P MACE), and 19% reduction in a broader composite that also included any ischemia-driven arterial revascularization (4-P MACE). Repatha also reduced the risk of heart attack by 36%. In a cohort of patients included in a lipid sub-study, the median achieved LDL-C was 45 mg/dL compared to 109 mg/dL in the placebo arm. 

"The VESALIUS-CV results deliver clear and compelling evidence that intensive LDL-C lowering is critical to reducing cardiovascular risk," said Jay Bradner, M.D., executive vice president of Research and Development at Amgen. "Repatha has once again demonstrated its ability to protect patients from the cardiovascular events they fear most, like heart attack or stroke, even before one occurs. These findings reinforce the urgent need to translate today's evidence into tomorrow's clinical practice. With a decade of real-world experience and proven benefit across the continuum of cardiovascular disease, every patient facing elevated risk due to uncontrolled LDL-C should be considered for Repatha."

Repatha significantly reduced the risk of most secondary endpoints, including the following composites: heart attack, ischemic stroke or any ischemia-driven revascularization; CHD death, heart attack or revascularization; cardiovascular death, heart attack or ischemic stroke; and CHD death or heart attack. In addition, there were numerical trends for reduced mortality rates in the Repatha arm, including cardiovascular death (21% relative risk reduction), CHD death (11% relative risk reduction) and all-cause death (20% relative risk reduction), as well as a trend toward lower ischemic stroke (21% relative risk reduction).

"Building on the success of FOURIER, in which we showed that adding evolocumab to statin therapy in patients with a prior heart attack or stroke reduced the risk of subsequent major adverse cardiovascular events, we now show that in the much larger population of patients with atherosclerosis or diabetes, but without a prior heart attack or stroke, that adding evolocumab to their lipid regimen substantially reduces their risk of MACE," said Marc S. Sabatine, M.D., M.P.H., Chair of the TIMI Study Group and the Lewis Dexter, MD, Endowed Chair in Cardiovascular Medicine at Brigham and Women's Hospital. "In both FOURIER and VESALIUS-CV, patients in the evolocumab arm achieved median LDL-C levels in the range of approximately 30 to 45 mg/dL, supporting such a target across a broad range of patients." 

Results also showed reduction in risk of cardiovascular events in the nearly 60% of trial participants who had diabetes, reinforcing the urgent need to manage LDL-C in these patients who remain largely undertreated.

"Cardiovascular disease remains the leading cause of mortality and morbidity for people living with diabetes, driven by risk factors including high LDL-C. Reducing this risk needs to be prioritized in primary care settings where the majority of people living with diabetes receive care," said Osagie Ebekozien M.D., M.P.H., CPHQ, Chief Quality Officer, American Diabetes Association. "The American Diabetes Association is committed to transforming diabetes care through the implementation of evidence-based guidelines for managing hyperlipidemia and reducing cardiovascular risk."

No new safety signals were identified, and tolerability was consistent with the current prescribing information in the U.S. Only treatment-emergent adverse events that were serious or led to discontinuation were captured. 

Cardiovascular disease is the leading cause of death worldwide.1 Every 40 seconds, a heart attack or stroke occurs in the U.S., and 75% of those are first-time events.1 Recent research shows that more than 99% of people who experience a first-time cardiovascular event have at least one traditional risk factor, including high LDL-C which is one of the most modifiable risk factors for heart attack or stroke.2

Repatha was first approved in 2015 and has since been used by more than 6.7 million patients globally.3,4 Earlier this year, the U.S. Food and Drug Administration broadened the approved use of Repatha to include adults at increased risk for major adverse CV events due to uncontrolled LDL-C. All U.S. patients can now access Repatha through AmgenNow, the company's direct-to-patient program, at a monthly price of $239, nearly 60% lower than the current U.S. list price.

About the VESALIUS-CV Trial
VESALIUS-CV is a Phase 3, double-blind, randomized, placebo-controlled global clinical trial designed to evaluate the impact of LDL-C lowering with evolocumab on MACE in adults at high CV risk without prior heart attack or stroke. 

VESALIUS-CV enrolled more than 12,000 patients with known atherosclerotic cardiovascular disease (ASCVD) or high-risk diabetes, who had no history of heart attack or stroke, an LDL-C ≥ 90 mg/dL, or non-high-density lipoprotein cholesterol (non-HDL-C) ≥ 120 mg/dL, or apolipoprotein B ≥ 80 mg/dL; and treated with highest tolerated dose of statin and/or ezetimibe. The median baseline LDL-C was 122 mg/dL (IQR, 104-149 mg/dL) on local lab testing. Participants were randomized to receive Repatha or placebo in addition to optimized lipid-lowering therapy and were followed for a median of approximately 4.6 years. 

Amgen's Commitment to Cardiovascular Innovation
Cardiovascular disease (CVD) remains a major global health threat, linked to multiple interrelated risk factors like high LDL-C, Lp(a), obesity, diabetes and hypertension.5,6 These risks often coexist and require a comprehensive approach to prevention and care. Amgen is taking bold action, building on decades of leadership in CVD through LDL-C management to advance additional innovative, investigational treatments in the pipeline targeting common drivers of CVD. By combining scientific innovation with strategic partnerships to drive earlier testing, better care and broader access, Amgen's efforts reflect a sustained commitment to advancing both the science and the system of CV care.

About Repatha
Repatha is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Repatha binds to PCSK9 and inhibits circulating PCSK9 from binding to the low-density lipoprotein (LDL) receptor (LDLR), preventing PCSK9-mediated LDLR degradation and permitting LDLR to recycle back to the liver cell surface. By inhibiting the binding of PCSK9 to LDLR, Repatha increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels. 

Repatha is the most extensively studied PCSK9 inhibitor, with clinical and real-world evidence across diverse populations and CV risk profiles.7 The clinical benefits and safety of Repatha have been studied for 15 years in 51 clinical trials with over 57,000 patients.8 Repatha is approved in 74 countries, including the U.S., Japan, Canada and in all 28 countries that are members of the European Union.9 Applications in other countries are pending.

INDICATIONS
Repatha is a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor indicated:

To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults at increased risk for these events.
As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in:

adults with hypercholesterolemia.
adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).
adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).

The safety and effectiveness of Repatha® have not been established in pediatric patients with HeFH or HoFH who are younger than 10 years old or in pediatric patients with other types of hypercholesterolemia. For full prescribing information, visit www.Repatha.com.

IMPORTANT SAFETY INFORMATION  

Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.
Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.
Adverse Reactions in Adults with Primary Hypercholesterolemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Adverse Reactions in the FOURIER Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

Adverse Reactions in Pediatric Patients with HeFH: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, headache, oropharyngeal pain, influenza, and upper respiratory tract infection.
Adverse Reactions in Adults and Pediatric Patients with HoFH: In a 12-week study in 49 patients, the adverse reactions that occurred in at least two patients treated with Repatha® and more frequently than placebo were: upper respiratory tract infection, influenza, gastroenteritis, and nasopharyngitis. In an open-label extension study in 106 patients, including 14 pediatric patients, no new adverse reactions were observed.
Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Please  see  full Prescribing Information. 

About Amgen 
Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube and Threads. 

Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast), our acquisitions of ChemoCentryx, Inc. or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.

Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions, including those resulting from geopolitical relations and government actions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our sustainability objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

Any scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses.

CONTACT: Amgen, Thousand Oaks
Madison Howard, 773-636-4910 (media)
Elissa Snook, 609-251-1407 (media)
Casey Capparelli, 805-447-1746 (investors)  

REFERENCES

Martin, S. S., Aday, A. W., Allen, N. B., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Bansal, N., Beaton, A. Z., Commodore-Mensah, Y., Currie, M. E., Elkind, M. S. V., Fan, W., Generoso, G., Gibbs, B. B., Heard, D. G., Hiremath, S., Johansen, M. C., Kazi, D. S., Ko, D., … American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Committee. (2025). 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation, 151(8), e41–e660. https://doi.org/10.1161/CIR.0000000000001303
Le, H. et al. (2025). Very High Prevalence of Nonoptimally Controlled Traditional Risk Factors at the Onset of Cardiovascular Disease. JACC, Volume 86 (Number 14)
Shapiro MD. Circulation. 2022;146(15):1120-1122.  
Rao SV, O'Donoghue ML, Ruel M, et al. Circulation. 2025;151(13):e771-e862.
Vasan, R. S., Enserro, D. M., Xanthakis, V., Beiser, A. S., & Seshadri, S. (2022). Temporal Trends in the Remaining Lifetime Risk of Cardiovascular Disease Among Middle-Aged Adults Across 6 Decades: The Framingham Study. Circulation, 145(17), 1324–1338. https://doi.org/10.1161/CIRCULATIONAHA.121.057889
Tsimikas, S, Marcovina, S. Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds: JACC Review Topic of the Week. JACC. 2022 Aug, 80 (9) 934–946. https://doi.org/10.1016/j.jacc.2022.06.019 MAC: REF-99099
Data on File; Amgen, 2025.
Data on File; Amgen, 2025.
Data on File; Amgen, 2025.

SOURCE Amgen

Bitcoin's three-year bull market remains structurally intact if ~$100K holds, according to Galaxy Research.

The crypto market continues to navigate in choppy conditions, following the devastating crash on October 10th that was arguably one of the most severe and rapid liquidation events. The flash crash triggered massive liquidation volumes across the market, which led to cascading liquidations within hours that swept through leveraged positions.

The fallout from these liquidations has contributed to broader market weakness, with many assets struggling to regain momentum. As a result of the market chaos, Bitcoin’s year-end target has been revised downward.

Bitcoin Target Slashed
Galaxy Research highlighted in a recent tweet that 72 of the top 100 crypto assets by market capitalization are currently trading at least 50% below their previous all-time highs. Macro factors have compounded these market challenges. According to the platform, this year has been characterized by significant whale distribution, rotation into competing narratives such as AI, gold, and stablecoins, and underperformance among BTC-focused treasury companies.

Hence, Galaxy Research stated that it has now revised its 2025 year-end target for Bitcoin from $185,000 to $120,000. However, it explained that Bitcoin has entered a new phase and added that the asset is in its ‘maturity era’ – in which institutional absorption, passive flows, and lower volatility dominate.

As such, if Bitcoin can maintain the ~$100,000 level, Galaxy Research said that the almost three-year bull market will remain structurally intact even though the pace of future gains may be slower.

“Still, we think nearing prior all-time highs before year-end is a reasonable target for short-term bulls.”

Base-Building Phase Underway
Coinbase Institutional views October’s crypto sell-off as a potential market reset instead of a cycle top. In its recent insights, the platform said that excess leverage has been cleared, fundamentals remain solid, and institutional investors are gradually returning.

It also found that smart capital is targeting EVM chains, real-world assets (RWAs), and yield protocols, which reflects selective re-risking rather than a retreat. Although liquidity gaps persist and macro uncertainty continues, structural demand is strengthening. The firm sees this as a “base-building” phase that could set the foundation for the next upward move in the crypto market.

You may also like:

Bitcoin Dips Below $100K Again as Analyst Waves the White Flag – ‘See You in 4 Years’

Bitcoin Faces Mid-Bull Test with LTHs Cashing Out as STHs Hold the Line

NewYorkCoin Skyrockets on Social Feeds as Zohran Mamdani’s Win Triggers a Political Crypto Frenzy

Adding perspective on investor behavior, Galaxy CEO Mike Novogratz attributed the slowdown to long-term holders rebalancing their portfolios after an extended bull run. He noted that while the diversification of large, concentrated positions may temporarily weigh on prices, it is healthy for the medium and long term.

Novogratz also suggested that cycle highs have likely not yet been reached. Looking ahead, he expects a new Federal Reserve chair by year-end to take a more dovish approach, which could provide the narrative needed to support the next much-anticipated upward leg in crypto prices.

Tags:

Bitcoin has fallen below critical technical thresholds, prompting warnings from major analytics firms about an extended period of decline. At the time of writing, the cryptocurrency is trading at $102,298, indicating a 0.35% increase over the past 24 hours. Weekly losses have reached nearly 7%, while monthly declines exceed 16%.

Source: CoinMarketCap

CryptoQuant identified an extremely bearish phase for the digital asset. On-chain data reveals troubling signals as BTC hovers around the $102,000 mark.

Critical Support Level BrokenThe 365-day moving average has been breached. Bitcoin fell below the $102,000 threshold that previously marked the bottom of the bull cycle. This technical and psychological support level held significance for market participants.

Source: CryptoQuant

CryptoQuant's Bull Score Index reached zero for the first time in over three years. The last occurrence preceded the previous bear market. Traders' on-chain realized price bands suggest potential movement toward $72,000 if recovery fails above $100,000.

The Metcalfe network valuation model indicates $91,000 as the next level of structural support. Failure to reclaim the 365-day moving average could trigger broader corrections. The analytics firm notes similarities to 2021, when breaking below this metric initiated a prolonged drawdown.

Market fundamentals have weakened over recent weeks. Increased outflows, reduced network activity, and flattening valuation metrics paint a concerning picture. Bitcoin touched $98,000 on November 4, marking the local bottom and the first drop below $100,000 since July.

Bloomberg's Mike McGlone projects a possible 50% decline if current trends continue. He suggests the cryptocurrency could revert to its 48-month moving average near $56,000. McGlone describes this pattern as normal behaviour following extended rallies similar to 2025.

Mixed Signals from Market IndicatorsXWIN Research Japan highlighted declining Market Value to Realized Value ratios. The MVRV has fallen to historical lows, ranging from 1.8 to 2.0. These levels typically coincide with mid-term market bottoms or early recovery phases.

Bitcoin: MVRV Ratio, Source: CryptoQuant

Glassnode's analysis offers a more measured perspective. The firm's report titled "Defending $100K" suggests the current situation represents a normal correction within the ongoing cycle. Data shows 71% of market supply remains profitable. Unrealized losses account for just 3.1% of market capitalization.

Market analysts remain divided on the trajectory of Bitcoin. As we previously covered, Cathie Wood of ARK Invest reduced her long-term price projection by $300,000. She cited concerns about stablecoins eroding Bitcoin's store-of-value role in emerging markets.